Toregem Raises Approximately USD 5.3 Million (JPY 850 Million) in Pre-Series C Financing;Total Past Funding Exceeds USD 29 Million (JPY 4.6 Billion）With this fundinig, we will accelerate the clinical development of the world's first tooth regeneration treatment.

Toregem raised approximately USD 5.3 Million (JPY 850 million) in Pre-Series C financing round fundingThrough this funding, Toregem’s cumulative equity financing has reached approximately JPY 2.6 billion, and its cumulative funding, including grants and subsidies, has exceeded USD 29 Million (JPY 4.6 billion).
With this funding, Toregem will conduct Phase II clinical trials of TRG035, a humanized anti-USAG-1 antibody, in Japan, prepare for future clinical development in the United States, and further accelerate the clinical development of what could become the world’s first tooth regeneration therapy.

Press release